Stellar Biotechnologies Beginning Preclinical
Port Hueneme, CA - June 10, 2010, Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) will initiate preclinical testing of its immunogenic agent, Stellar KLH/NeoA, in anticipation of filing an IND application for its Stellar KLH/NeoA platform. Drug safety, toxicology and immunogenicity studies to begin shortly, should be completed by December 2010, and positive results will generate a filing to begin human testing.
Stellar’s VP, Product Development, Herbert Chow, Ph.D., said, “Building a new Stellar KLH product platform based on our developing IP is a major step. As demonstrated by Dendreon’s prostate cancer vaccine and recent news from Bristol-Myers on metastatic melanoma, immunotherapy may become foundational in cancer treatment. While Stellar KLH can make a significant contribution in oncology, we have confidence that the product platform we are developing can enable novel therapeutics and targeted diagnostics for other indications.”
Darrell Brookstein, VP
About Stellar Biotechnologies, Inc (TSX-V: KLH): Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is used in conjugate therapeutic vaccines and other biomedical products. A world leader in the production of KLH, Stellar maximizes the commercial impact of its Stellar KLH production platform and IP, expanding the sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the rare keyhole limpet, and Stellar’s technology for limpet maintenance, non-lethal extraction and refinement of the molecule differentiate it for growing research and pharmaceutical markets.
This Company news release contains certain "forward-looking" statements and information relating to the Company that are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors and strategic partners, the interest rate environment, governmental regulation and supervision, seasonality, technological change, changes in industry practices, and one-time events. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.